EGFR and non-small cell lung carcinoma: These efficacy, safety, and convenience outcomes leave few doubts about an almost complete substitution of intravenous amivantamab with subcutaneous amivantamab in the near future, with an enhancement of the role of this drug in the treatment of advanced EGFR mutant NSCLC (Table 3).